Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: a patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials

被引：0
|
作者：
Moura, F. [1 ]
Wiviott, S. [1 ]
Chertow, G. [2 ,3 ]
Dwyer, J. [4 ]
Gause-Nilsson, I [5 ]
Johansson, P. [5 ]
Langkilde, A. [5 ]
McMurray, J. [6 ]
Mosenzon, O. [6 ]
Raz, I [7 ]
Rossing, P. [8 ]
Wheeler, D. [9 ]
Sabatine, M. [1 ]
Heerspink, H. [10 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Div Cardiovasc Med, TIMI Study Grp, Boston, MA USA
[2] Dept Epidemiol & Populat Hlth, Sch Med, Stanford, CA USA
[3] Dept Med, Stanford, CA USA
[4] Univ Utah Hlth Care, Salt Lake City, UT USA
[5] AstraZeneca, Cambridge, England
[6] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland
[7] Hebrew Univ Jerusalem, Hadassah Med Ctr, Diabet Unit, Jerusalem, Israel
[8] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
[9] UCL, Dept Renal Med, London, England
[10] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands
来源：
EUROPEAN HEART JOURNAL | 2022年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2407 / 2407
页数：1
相关论文
共 43 条
  • [31] Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events
    Julio Rosenstock
    Nikolaus Marx
    Dietmar Neubacher
    Thomas Seck
    Sanjay Patel
    Hans-Juergen Woerle
    Odd Erik Johansen
    Cardiovascular Diabetology, 14
  • [32] DAPAGLIFLOZIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND PRIOR MYOCARDIAL INFARCTION: A SUB-ANALYSIS FROM DECLARE TIMI-58 TRIAL
    Furtado, Remo Holanda de Mendonca
    Bonaca, Marc
    Raz, Itamar
    Zelniker, Thomas
    Mosenzon, Ofri
    Cahn, Avivit
    Kuder, Julia
    Murphy, Sabina
    Bhatt, Deepak L.
    Leiter, Lawrence
    McGuire, Darren
    Wilding, John P. H.
    Ruff, Christian
    Gause-Nilsson, Ingrid A. M.
    Fredriksson, Martin
    Langkilde, Anna Maria
    Sabatine, Marc
    Wiviott, Stephen
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 1 - 1
  • [33] Effects of Dapagliflozin in Heart Failure, Type 2 Diabetes, and Neuropathy - A Patient-Level Meta-Analysis of DAPA-HF and DELIVER
    Butt, Jawad H.
    Jhund, Pardeep S.
    Docherty, Kieran
    Bachus, Erasmus
    Claggett, Brian
    Hernandez, Adrian F.
    Lam, Carolyn S.
    Inzucchi, Silvio
    Martinez, Felipe
    De Boer, Rudolf A.
    Kosiborod, Mikhail N.
    Desai, Akshay S.
    Kober, Lars
    Ponikowski, Piotr
    Sabatine, Marc S.
    Shah, Sanjiv J.
    Vaduganathan, Muthiah
    Solomon, Scott
    McMurray, John J.
    CIRCULATION, 2023, 148
  • [34] Effects of dapagliflozin in heart failure according to duration of type 2 diabetes: a patient-level meta-analysis of DAPA-HF and DELIVER
    Butt, J.
    De Boer, R. A.
    Hernandez, A.
    Inzucchi, S. E.
    Kosiborod, M.
    Koeber, L.
    Lam, C. S. P.
    Martinez, F. A.
    Ponikowski, P.
    Sabatine, M. S.
    Shah, S.
    Vaduganathan, M.
    Jhund, P. S.
    Solomon, S. D.
    Mcmurray, J. J., V
    EUROPEAN HEART JOURNAL, 2024, 45
  • [35] Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial (vol 9, pg 743, 2021)
    Heerspink, H. J. L.
    Jongs, N.
    Chertow, G. M.
    LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (10): : E10 - E10
  • [36] The Portfolio Diet and HbA1c in Adults Living with Type 2 Diabetes Mellitus: A Patient-Level Pooled Analysis of Two Randomized Dietary Trials
    Kavanagh, Meaghan E.
    Back, Songhee
    Chen, Victoria
    Glenn, Andrea J.
    Viscardi, Gabrielle
    Houshialsadat, Zeinab
    Sievenpiper, John L.
    Kendall, Cyril W. C.
    Jenkins, David J. A.
    Chiavaroli, Laura
    NUTRIENTS, 2024, 16 (17)
  • [37] Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials
    Fonseca, Vivian A.
    DeVries, J. Hans
    Henry, Robert R.
    Donsmark, Morten
    Thomsen, Henrik F.
    Plutzky, Jorge
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2014, 28 (03) : 399 - 405
  • [38] Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes
    Cooper, Mark E.
    Perkovic, Vlado
    McGill, Janet B.
    Groop, Per-Henrik
    Wanner, Christoph
    Rosenstock, Julio
    Hehnke, Uwe
    Woerle, Hans-Juergen
    von Eynatten, Maximilian
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2015, 66 (03) : 441 - 449
  • [39] Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH A post hoc, pooled, patient-level analysis of 6 randomized controlled trials
    Porcellati, Francesca
    Lin, Jay
    Lucidi, Paola
    Bolli, Geremia B.
    Fanelli, Carmine G.
    MEDICINE, 2017, 96 (05)
  • [40] More satisfied, but why? A pooled patient-level analysis of treatment satisfaction following the initiation of insulin glargine vs. comparators in insulin-naive patients with type 2 diabetes mellitus
    Polonsky, W.
    Traylor, L.
    Wei, W.
    Shi, R.
    Ameer, B.
    Vlajnic, A.
    Nicolucci, A.
    DIABETES OBESITY & METABOLISM, 2014, 16 (03): : 255 - 261
12345